Antiepileptic drugs influences on body weight in people with epilepsy

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 103-114

  Hamed, Sherifa Ahmed ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

adiponectin; antiepileptic drugs; galanin; ghrelin; insulin; leptin; metabolic adverse effects; neuropeptide Y; obesity; weight

Indexed keywords

ADIPONECTIN; ANTICONVULSIVE AGENT; GALANIN; GHRELIN; INSULIN; LEPTIN; NEUROPEPTIDE Y; VALPROIC ACID; HORMONE; NEUROPEPTIDE;

BODY WEIGHT; ENERGY BALANCE; ENERGY EXPENDITURE; EPILEPSY; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPOTHALAMUS; NONHUMAN; PATHOGENESIS; REVIEW; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; METABOLISM; RETROSPECTIVE STUDY;

ANTICONVULSANTS; BODY WEIGHT; CROSS-SECTIONAL STUDIES; EPILEPSY; HORMONES; HUMANS; NEUROPEPTIDES; RETROSPECTIVE STUDIES;

EID: 84916930962     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.991716     Document Type: Review

References (156)

1. Isojärvi JI, Taubøll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001;42(3): 305-10
2. Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43(5):514-17
3. Verrotti A, Basciani F, De Simone M, et al. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17(4):265-8
4. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11(4):556-62
5. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17(11):781-91
6. Hamed SA. Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res 2007;75(1):1-9
7. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Paediatr Neurol 2009;13(3):261-8
8. Bhatt R, Bhatt S, Rameshwar P, Siegel A. Amygdaloid kindled seizures induce weight gain that reflects left hemisphere dominance in rats. Physiol Behav 2004;82(2-3):581-7
9. Ganaraj B, Jeganathan PS. Involvement of basolateral nucleus and central nucleus of amygdala in the regulation of ingestive behavior in rat. Indian J Med Res 1998;108:98-103
10. Janousek J, Barber A, Goldman L, Klein P. Obesity in adults with epilepsy. Epilepsy Behav 2013;28(3):391-4
11. Ladino LD, Ronquillo LH, Tellez-Zenteno JF. Obesity and its association with generalized epilepsy, idiopathic syndrome, and family history of epilepsy. Epileptic Disord 2014;16(3): 343-53
12. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 2003;32(4):1005-24
13. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1977;24(3):240-4
14. Easter D, O'Brvan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-A reappraisal. Seizure 1997; 6(2):121-5
15. Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbamazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103(3):588-93
16. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53(1):230-2
17. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22(5):361-4
18. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28(2):126-9
19. Maggioni F, Ruffatti S, Dainese F, et al. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005;6(4): 322-4
20. Drieling T, Biedermann NC, Scharer LO, et al. Psychotropic drug-induced changes of weight: a review. Fortschr Neurol Psychiatr 2007;75(2):65-80
21. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012; 28(6):1027-37
22. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(5 Suppl 2): S53-67
23. Wehner T, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16(3):423-5
24. Mourand I, Crespel A, Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013; 54(1):e5-8
25. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000;41(1):23-8
26. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21(8): 904-19
27. Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003;18(2):133-9
28. Morrell MJ, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54(2-3):189-99
29. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar 1 disorder. Am J Psychiatry 2006; 163(7):1199-201
30. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8(2):175-81
31. Zarzar MN, Graham J, Roberts J, et al. Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. MedGenMed 2007;9(2):41
32. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008;118(1): 4-18
33. Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009;24(3):150-8
34. Pickrell WO, Lacey AS, Thomas RH, et al. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013; 84(7):796-9
35. Loiseau P. Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 1999;40(S9):S14-19
36. Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003; 56(2-3):121-6
37. Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: weight loss associated with levetiracetam. BMJ 2003;327(7420):905
38. Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. Epilepsia 2008;49(2):308-15
39. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999;60(Suppl 21):5-9
40. Sheth R. Adolescent issues in epilepsy. J Child Neurol 2002;17(Sl2):S23-7
41. Hamed SA, Hamed EA, Kandil MR, et al. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res 2005;66(1-3):173-83
42. Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci 2005;98(4):340-53
43. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006; 296(1):79-86
44. Hamed SA, Hamed SA, Shokry M, et al. The reproductive conditions and lipid profile in females with epilepsy. Acta Neurol Scand 2007;115(1):12-27
45. Hamed SA. Atherosclerosis in epilepsy: its causes and implications. Epilepsy Behav 2014. [Epub ahead of print]
46. Aydin K, Serdaroglu A, Okuyaz C, et al. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol 2005;20(10): 848-51
47. Brill J, Lee M, Zhao S, et al. Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J Neurosci 2006;26(25):6813-22
48. Cansu A, Serdaroglu A, Camurdan O, et al. Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate. Horm Res Paediatr 2011;76(1):65-71
49. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84(3): 488-95
50. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409(6817):194-8
51. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999; 22(2):221-32
52. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein and adiponectin. Curr Opin Lipidol 2002;13(1): 51-9
53. Bray G. Peptides affect the intake of specific nutrients and the sympathetic nervous system. Am J Clin Nutr 1992;55(1 Suppl): 265S-71S
54. Ponsalle P, Srivastava LS, Uht RM, White JD. Glucocorticoids are Required for Food Deprivation-Induced Increases in Hypothalamic Neuropeptide Y Expression. J Neuroendocrinol 1992;4(5):585-91
55. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7(6):1189-92
56. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278(5335):135-8
57. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature 1996;380(6571):243-7
58. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92(4):573-85
59. Soria-Gomez E, Bellocchio L, Reguero L, et al. The endocannabinoid system controls food intake via olfactory processes. Nat Neurosci 2014;17(3):407-15
60. Jegou S, Blasquez C, Delbende C, et al. Regulation of alpha-melanocyte-stimulating hormone release from hypothalamic neurons. Ann N Y Acad Sci 1993;680: 260-78
61. Armbruszt S, Abraham H, Figler M, et al. Cocaine- and amphetamine-regulated transcript (CART) peptide immunoreactivity in feeding- and reward-related brain areas of young OLETF rats. J Chem Neuroanat 2013;50-51:75-84
62. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res 2006;153: 209-35
63. Arase K, York DA, Shimizu H, et al. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol 1988; 255(3 Pt 1):E255-9
64. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84(3):491-5
65. Cegla J, Troke RC, Jones B, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 2014;63(11):3711-20
66. Harrold JA. Hypothalamic control of energy balance. Curr Drug Targets 2004;5(3): 207-19
67. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104(4):531-43
68. Smith GP, Jerome E, Norgren R. Afferent axons in abdominal vagus mediate the satiety effect of cholycystokinin in rats. Am J Physiol 1985;249(5 Pt 2):R638-41
69. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterization of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002;143(3):775-83
70. Vollenweider P, Randin D, Tappy L, et al. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994;93(6):2365-71
71. Haynes WG, Morgan DA, Walsh SA, et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997;100(2):270-8
72. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411(6836): 480-4
73. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003;24(1):1-10
74. Kim MS, Pak YK, Jang PG, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci 2006;9(7):901-6
75. Harvey J, Ashford ML. Leptin in the CNS: much more than a satiety signal. Neuropharmacology 2003;44(7):845-54
76. Kanai F, Ito K, Todaka M, et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI2-kinase. Biochem Biophys Res Commun 1993; 195(2):762-8
77. Sivitz WI, Walsh SA, Morgan DA, et al. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997;138(8): 3395-401
78. Russell CD, Petersen RN, Rao SP, et al. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol 1998;275(3 Pt 1):E507-15
79. Aiston S, Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin. Diabetes 1999;48(1):15-20
80. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274(5290):1185-8
81. Cases JA, Gabriely I, Ma XH, et al. Physiological increase in plasma leptin inhibits insulin secretion in vivo. Diabetes 2001;50(2):348-52
82. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36
83. Shanley LJ, O'Malley D, Irving AJ, et al. Leptin inhibits epileptiform-like activity in rat hippocampal neurons via PI3-kinase-driven activation of BK channels. J Physiol 2002;545(Pt 3):933-44
84. Spanswick D, Smith MA, Mirshamsi S, et al. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 2000;3(8): 757-8
85. Joffe H, Hall JE, Cohen LS, et al. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 2003;11(2):99-108
86. Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43(4):446-51
87. El-Khatib F, Rauchenzauner M, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007;16(3):226-32
88. Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine and oxcarbamazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103(3):588-93
89. Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39(5):579-84
90. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1996; 313(2):75-9
91. Greco R, Latini G, Chiarelli F, et al. Leptin, ghrelin and adiponectin in epileptic patients treated with valproic acid. Neurology 2005;65(11):1808-9
92. Hamed SA, Abdellah MM. Trace elements and electrolytes homeostasis and their relation to antioxidant enzyme activity in brain hyperexcitability of epileptic patients. J Pharmacol Sci 2004;96(4):349-59
93. Hamed SA, Abdellah MM, El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci 2004; 96(4):465-73
94. Hamed SA, Hamed EA, Hamdy R, Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in Adult patients with epilepsy. Epilepsy Res 2007; 74(2-3):183-92
95. Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006;47(9):1460-4
96. Sonmez FM, Zaman D, Aksoy A, et al. The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy. Seizure 2013;22(10): 856-61
97. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45(4):444-50
98. Tokgoz H, Aydin K, Oran B, Kiyici A. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 2012; 28(7):1049-53
99. Prodam F, Bellone S, Casara G, et al. Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid. Epilepsia 2010;51(2):312-15
100. Taskin E, Atli B, Kiliç M, et al. Serum, urine, and saliva levels of ghrelin and obestatin pre- and post-treatment in pediatric epilepsy. Pediatr Neurol 2014; 51(3):365-9
101. Verrotti A, Greco R, Latini G, et al. Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate. Neuroendocrinology 2014;79(3):157-62
102. Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55(5): 729-32
103. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41(6):666-70
104. Meeker RB, Myers RD. GABA and glutamate: possible metabolic intermediaries involved in the hypothalamic regulation of food intake. Brain Res Bull 1980;5:253-9
105. Luef GJ, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003; 55(1-2):53-8
106. Johannessen CU. Mechanism of action of Valproate: a commentary. Neurochem Int 2000;37(2-3):103-10
107. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: relation to obesity. Epilepsy Res 1993;16(1):55-64
108. Grill V, Qvigstad E. Fatty acids and insulin secretion. Br J Nutr 2000;83(Suppl 1): S79-84
109. MacGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51(1):7-18
110. Roden M, Krssak M, Stingl H, et al. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 1999;48(2):358-64
111. Yoshikawa H, Tajiri Y, Sako Y, et al. Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal home box. Metabolism 2001;50(5):613-18
112. Shi Y, Kanaani J, Menard-Rose V, et al. Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab 2000;279(3):E684-94
113. Vorbrodt AW, Dobrogowska DH, Kozlowski PB, et al. Immunogold study of effects of prenatal exposure to lipopolysaccharide and/or valproic acid on the rat blood-brain barrier vessels. J Neurocytol 2005;34(6):435-46
114. Reiterer EE, Sudi KM, Mayer A, et al. Changes in leptin and insulin composition in obese children during a weight reduction program. J Pediatr Endocrinol Metab 1999; 12(6):853-62
115. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004;145(2): 799-808
116. Lagace DC, Mcleod RS, Nachtigal MW. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 2004; 145(12):5493-503
117. Nisoli E, Carruba MO, Tonello C, et al. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 2000;49(3):319-24
118. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51(6):1884-8
119. Lampl Y, Eshel Y, Rapaport A, Sarova-Pinhas I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991;14(3):251-5
120. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc) 2005;41(8):547-55
121. Uludag IF, Kulu U, Sener U, et al. The effect of carbamazepine treatment on serum leptin levels. Epilepsy Res 2009;86(1):48-53
122. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19(4):394-6
123. Stephen LJ, Parker P, Kelly K, et al. Adjunctive pregabalin for uncontrolled partial-onset seizures: findings from a prospective audit. Acta Neurol Scand 2011; 124(2):142-5
124. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47(12):1025-33
125. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(Suppl 1):S66-71
126. Klein KM, Theisen F, Knake S, et al. Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry 2008;79(5):590-3
127. Schütt M, Brinkhoff J, Drenckhan M, et al. Weight reducing and metabolic effects of topiramate in patients with migraine-an observational study. Exp Clin Endocrinol Diabetes 2010;118(7):449-52
128. Ozcelik AA, Serdaroglu A, Bideci A, et al. The effect of topiramate on body weight and ghrelin, leptin, and neuropeptide-Y levels of prepubertal children with epilepsy. Pediatr Neurol 2014;51(2):220-4
129. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005;38(4):295-300
130. Kirov G, Tredget J. Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series. BMC Psychiatry 2005;5:19
131. Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 2013;33(1):90-4
132. Wilding J, Van Gaal L, Rissanen A, OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28(11): 1399-410
133. Richard D, Ferland J, Lanlonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10): 961-6
134. Davidson MH, Tonstad S, Oparil S, et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index 27 kg/m(2). Am J Cardiol 2013;111(8): 1131-8
135. Lalonde J, Samson P, Poulin S, et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004;80(4): 415-20
136. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000;8(9):656-63
137. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12(10): 1658-69
138. Davalli AM, Perego C, Folli FB, Bosi E. Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol 2012; 49(1):75-9
139. Khanna V, Arumugam S, Roy S, et al. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008;12(1):81-90
140. Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003;28(7): 1292-9
141. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000;16(10):967-75
142. Tremblay A, Chaput JP, Berube-Parent S, et al. The effect of topiramate on energy balance in obese men: a 6-month doubleblind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007;63(2):123-34
143. Shi RF, Wang KL, Li QH, et al. Changes of body weight and galanin in epileptic children treated with topiramate. Zhonghua Er Ke Za Zhi 2007;45(3):199-202
144. Theisen FM, Beyenburg S, Gebhardt S, et al. A prospective study of body weight and serum leptin levels in patients treated with topiramate. Clin Neuropharmacol 2008;31(4):226-30
145. Liang Y, She P, Wang X, Demarest K. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 2006;55(10):1411-19
146. Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009;119(4):233-8
147. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33(12): 2922-33
148. McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag 2012;8:219-41
149. Gadde KM, Kopping MF, Wagner HR 2nd, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012;172(20): 1557-15564
150. Kim DW, Yoo MW, Park KS. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. Epilepsy Behav 2012;23(4):497-9
151. Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem 2010;18(1):14-18
152. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 2012;209:433-66
153. Kopelman PG. Obesity as a medical problem. Nature 2000;404(6778):635-43
154. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161(13):1581-6
155. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001;25(6):805-10
156. Parhami F, Tintut Y, Ballard A, et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88(9):954-60